INDAPTUS THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.12 USD | -1.40% |
|
+4.43% | +20.45% |
| May. 08 | Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 14 | Top Premarket Gainers | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 46.7 | 12.18 | 14.79 | 18.1 | - | - |
| Enterprise Value (EV) 1 | 46.7 | 12.18 | 14.79 | 18.1 | 18.1 | 18.1 |
| P/E ratio | -3.02 x | -0.84 x | -0.96 x | -1.06 x | -1.52 x | -1.72 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 8,194 | 8,401 | 8,401 | 8,539 | - | - |
| Reference price 2 | 5.700 | 1.450 | 1.760 | 2.120 | 2.120 | 2.120 |
| Announcement Date | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -7.729 | -14.91 | -16.38 | -21.17 | -23.98 | -22.81 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -7.711 | -14.32 | -15.42 | -21.17 | -23.68 | -22.81 |
| Net income 1 | -3.584 | -7.711 | -14.32 | -15.42 | -21.17 | -23.68 | -22.81 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -4.890 | -1.890 | -1.730 | -1.830 | -2.000 | -1.395 | -1.230 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/20/21 | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -3.218 | -3.402 | -3.869 | -3.553 | -4.087 | -4.455 | -3.495 | -4.248 | -4.18 | -3.943 | -4.732 | -5.678 | -6.814 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.216 | -3.365 | -3.836 | -3.466 | -3.656 | -4.253 | -3.245 | -3.922 | -4.003 | -3.807 | -4.732 | -5.678 | -6.814 |
| Net income 1 | -3.216 | -3.365 | -3.836 | -3.466 | -3.656 | -4.253 | -3.245 | -3.922 | -4.003 | -3.807 | -4.732 | -5.678 | -6.814 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2200 | -0.4100 | -0.4600 | -0.4200 | -0.4400 | -0.5100 | -0.3900 | -0.4700 | -0.4700 | -0.4500 | -0.5600 | -0.5200 | -0.4700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/21/22 | 5/12/22 | 8/8/22 | 11/10/22 | 3/17/23 | 5/11/23 | 8/14/23 | 11/6/23 | 3/13/24 | 5/8/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 4/20/21 | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.12
USD
Average target price
10
USD
Spread / Average Target
+371.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.45% | 18.1M | |
| +29.77% | 48.16B | |
| -0.63% | 41.73B | |
| +43.51% | 41.03B | |
| -5.31% | 28.77B | |
| +10.60% | 25.59B | |
| -21.63% | 18.96B | |
| +8.04% | 12.92B | |
| +27.50% | 12.03B | |
| -3.13% | 11.77B |
- Stock Market
- Equities
- INDP Stock
- Financials Indaptus Therapeutics, Inc.